Osage Partners related stories
All articles and analysis
VC-backed SiFive taps Shenoy as VP of hardware engineeringSilicon Valley-based SiFive, a provider of commercial RISC-V processor IP, has named Sunil Shenoy as vice president of hardware engineering. Previously, Shenoy worked at Intel. SiFive is backed by Sutter Hill Ventures, Spark Capital and Osage University Partners.
- Osage Venture Partners leads seed round for Indico
Boston-based Indico, a provider of enterprise machine learning solutions for unstructured content, has secured $4 million in seed funding. Osage Venture Partners led the round with previous backers.406 Ventures, Boston Seed and Hyperplane.
- Connected2Fiber snags $8 mln
Milford, Massachusetts-based Connected2Fiber, a provider of an SaaS platform used by B2B connectivity providers to manage and transform market data, has secured $8 million in funding. The investors were Ascent Venture Partners, Nauta Capital, NXT Ventures and Osage Venture Partners.
- Aptinyx lands $70 mln Series B
Aptinyx Inc, a developer of treatments for neurologic disorders, has closed $70 million in Series B financing. Bain Capital Life Sciences led the round with participation from other investors that included Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management, Rock Springs Capital, New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Osage University Partners, Adams Street Partners and Beecken Petty O'Keefe & Company.
- Menlo Security inks $40 mln
Palo Alto, California-based Menlo Security, a provider of malware isolation, has raised $40 million in Series C funding, The investors included American Express Ventures, Ericsson Ventures, HSBC, JPMorgan Chase, General Catalyst, Sutter Hill Ventures, Osage University Partners and Engineering Capital.
- VC-backed Spero Therapeutics goes public
Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company focused on developing treatments for bacterial infections, has debuted its IPO after pricing its 5.5 million shares at $14 per share. Spero began trading on the NASDAQ under the ticker symbol “SPRO.” BofA Merrill Lynch, Cowen and Company LLC and Stifel are the lead underwriters. Spero’s backers include GV, RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.
- VC-backed Spero Therapeutics sets IPO pricing terms
Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company focused on developing treatments for bacterial infections, has priced its IPO of five million shares at a price between $14 and $16 per share. Spero is planning on trading the stock on the NASDAQ under the ticker symbol "SPRO." BofA Merrill Lynch, Cowen and Company LLC and Stifel are the lead underwriters. Spero's backers include GV, RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.
- VC-backed Spero Therapeutics files for IPO
Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company focused on developing treatments for bacterial infections, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company is planning on trading the stock on the NASDAQ under the ticker symbol "SPRO." BofA Merrill Lynch, Cowen and Stifel will serve as lead underwriters. Spero's backers include GV, RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.
- VC-backed Blade Therapeutics hires EVP of research
South San Francisco-based Blade Therapeutics, a biopharmaceutical company that treats fibrotic disease, has appointed Dr. Maria E. Fuentes as executive vice president of research. Previously, she was group director of fibrosis discovery biology at Bristol-Myers Squibb. Blade's backers include MPM Capital, Deerfield, Osage Partners, as well as the venture funds of Pfizer, Bristol-Myers Squibb and Novartis.